Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

Published 1 days agoGILD

Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

Gilead Sciences' Trodelvy, when paired with Merck's Keytruda, has exhibited notable success in combating advanced triple-negative breast cancer (TNBC). Results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial revealed a significant improvement in treatment outcomes. This combination therapy demonstrated a median progression-free survival of 11.2 months, markedly better than the 7.8 months for patients receiving standard chemotherapy alongside Keytruda, according to Reuters.

The trial also highlighted an improved median response duration for the Trodelvy-Keytruda treatment, clocking in at 16.5 months, compared to just 9.2 months in the chemotherapy group. Reuters reported that the safety profile of the combination therapy remained consistent with the known effects of each drug individually, and no new safety issues emerged.

These findings suggest the Trodelvy-Keytruda regimen could soon become a preferred option for treating advanced TNBC, offering a potential new standard of care for this particularly aggressive cancer subtype. However, ongoing evaluation and broader adoption are necessary to confirm its effectiveness on a wider scale.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Bristol-Myers Squibb Joins Forces with BioNTech in $11 Billion Cancer Drug Collaboration

Bristol-Myers Squibb Joins Forces with BioNTech in $11 Billion Cancer Drug Collaboration

5 minutes agoBMY

Bristol-Myers Squibb (BMS) has struck a major partnership with BioNTech SE to develop and market BNT327, an emerging drug aimed at cancer treatment. As part of this deal, BMS will make an initial payment of $1.5 billion to BioNTech. Reuters reported that this expansive agreement could potentially reach a total value of approximately $11 billion. Further details reveal that BMS may provide up to $2 billion in non-contingent anniversary payments by 2028, while BioNTech stands to receive up to $7.6 billion tied to milestone achievements in the drug's development. The focal point of this deal, BNT327, is a bispecific antibody that targets PD-L1 and VEGF-A proteins to boost the immune system's ability to detect tumors and slow their progression. The drug is currently being tested in more than 20 clinical trials, including two late-stage studies focused on various solid tumors. This collaboration with BioNTech is part of BMS's broader strategy to enhance its oncology portfolio, especially as patents for existing bestsellers like Opdivo and Eliquis near expiration. Meanwhile, BioNTech leverages its COVID-19 vaccine success to advance oncology treatments, including mRNA-based therapies and cutting-edge chemotherapy techniques. Such partnerships reflect a wider industry trend towards joint efforts in developing advanced cancer therapies.

No New LinkedIn Layoff Reports, Past Cuts Highlighted

No New LinkedIn Layoff Reports, Past Cuts Highlighted

20 minutes agoMSFT

As of June 2, 2025, there have been no recent reports confirming that LinkedIn has planned to cut 281 jobs in California. The most significant recent layoffs at the company were announced in October 2023, when LinkedIn revealed it would reduce approximately 668 positions across its engineering, product, talent, and finance departments. Earlier, in May 2023, LinkedIn had also announced a decision to cut 716 jobs and shut down its job application platform in mainland China. This move was driven by changes in customer behavior and slower revenue growth, as noted by KDRV News. Considering the absence of new reports regarding the alleged 281 job cuts, it appears this information may pertain to outdated events or another organization. LinkedIn's recent layoff strategies reflect adjustments to market shifts rather than emerging policy changes.

TSMC Eyes UAE for Semiconductor Plant Amid U.S. Concerns

TSMC Eyes UAE for Semiconductor Plant Amid U.S. Concerns

35 minutes agoTSM

Taiwan Semiconductor Manufacturing Co. (TSMC) is reportedly exploring the possibility of establishing a semiconductor manufacturing facility in the United Arab Emirates. This news comes as the UAE is considering financing substantial semiconductor projects with potential collaborations involving TSMC and Samsung Electronics, according to Reuters. However, U.S. officials have raised concerns about advanced AI chip technologies potentially making their way to China through the UAE. Talks are underway that involve the provision of U.S. oversight on chip production and shipments from any prospective factories in the UAE, highlighting the geopolitical complexities of the situation, as reported by The Decoder. For now, TSMC has indicated that it remains focused on its current international projects and does not have any new investment plans to reveal, as noted by the Taipei Times. This development underscores the delicate balance between global technological expansion and international security concerns in the semiconductor sector.

Meta Enhances Advertising with Advanced AI Tools

Meta Enhances Advertising with Advanced AI Tools

50 minutes agoMETA

Meta Platforms is making significant strides in automating its advertising processes by integrating advanced artificial intelligence (AI) technologies. One of its pivotal advancements, the Advantage+ Shopping Campaigns, introduced in August 2022, employs AI to streamline ad creation by automating up to 150 creative combinations. Following this, the AI Sandbox launched in May 2023, allowing advertisers to experiment with generative AI features like text variation and image creation to optimize their ads. Most notably, Meta has continued to expand its suite of AI-powered advertising tools, unveiling new features in November 2023 that enhance lead generation and automate targeting, creative aspects, placements, and budgeting optimizations. In December 2024, Meta announced the introduction of Andromeda, a sophisticated machine learning system aimed at improving the efficiency of ad recommendations. This development signifies a leap forward in AI-driven ad personalization. Earlier that year, in May, Meta also rolled out generative AI-powered ad creativity tools designed to help advertisers automate the creation of engaging ad content, including varied images and text. These innovations underscore Meta's strategy to leverage AI in automating ad creation, boosting efficiency, and enhancing campaign performance. This initiative aligns with the company's broader goal of utilizing AI to improve its advertising operations, as noted by a report from Reuters. The ongoing development and implementation of these AI tools demonstrate Meta's commitment to maintaining a competitive edge in the digital advertising landscape.